Navigation Links
PAREXEL Experts To Address Best-Practice Strategic Partnership Models To Increase Operating Efficiency, Development Effectiveness at Partnerships in Clinical Trials
Date:3/17/2011

onal visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.   For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform;
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
8. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
9. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
10. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
11. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014 Does your doctor know ... 800 doctors have recommended marijuana to the over 112,000 currently ... But the majority of the other roughly 20,300+ active physicians ... very little about it – even though a poll in ... adults say they have tried it. "With ...
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4District Court Decision Received In Remodulin Patent Case 2
... 3 Glufosfamide and Phase 2 Glufosfamide Plus ... Gemcitabine Clinical Trials to be Presented, REDWOOD CITY, Calif., ... announced two presentations,regarding its oncology product candidate glufosfamide. The presentations,will ... held,September 23 to 27, 2007, at the International Conference Center ...
... First Hsp90 Inhibitor to Enter Registration Trials, HAYWARD, ... ) today announced that it has successfully,reached a binding ... the design of its TIME-1 clinical trial, a pivotal ... treatment for patients with,multiple myeloma. Through the FDA,s Special ...
Cached Medicine Technology:Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 2Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO) 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 2Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 3Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 4Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 5Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 6Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma 7
(Date:8/30/2014)... Delhi, India (PRWEB) August 30, 2014 ... introduced low cost SEO service for small businesses. , ... or start-ups cannot afford costly search engine optimization service. ... budget of small businesses into account. , On ... said, “We have introduced this low cost SEO service ...
(Date:8/30/2014)... 2014 The establishment and creation ... been one of the main strategies of the ... positive impact around the world. , Architecturally stellar ... trained executives and trainers deliver L. Ron Hubbard's ... Vital statistics demonstrate that significant reduction in crime, ...
(Date:8/30/2014)... Acne is a common problem millions of American cope ... than a daily nuisance, for some, it can have a crippling ... even lead to dramatic mood swings and depression. , Those ... up their skin. In some cases, that can make the problem ... error, those on a quest for clearer skin can now view ...
(Date:8/30/2014)... VA (PRWEB) August 30, 2014 Seniors Guide, ... articles recently that focus on Alzheimer’s Disease, Dementia, and ... revealed to the public of being diagnosed with the Alzheimer’s, ... latest movie, “I’ll Be Me”. The movie, out on ... while focusing on his diagnosis of the disease – which ...
(Date:8/30/2014)... Manhattan Beach, Calif. (PRWEB) August 30, 2014 ... Carol Francis helps listeners understand how they unknowingly developed insomnia ... and have restful nights during. Tune in to the ... . The show airs live on August 30, and ... For more information on programming, go to DrCarolFrancisTalkRadio.com. ...
Breaking Medicine News(10 mins):Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2
... in a gene called FGFR2 could accelerate the development ... uterine cancer. Researchers at Washington University School of Medicine ... (TGen); the Wellcome Trust Sanger Institute, which is part ... Medicine reported the findings in the May 21, 2007, ...
... new study has shown the severe repercussions of high-fat food combined ... on liver and other vital organs. ,The study ... at Saint Louis University. ,As part of the study, ... a diet that was 40 percent fat and replete with high ...
... A nationwide study has been launched in US to determine ... and lorazepam, is more effective. ,Childhood seizures ... seizures can lead to brain damage or even death ... two drugs currently prescribed to tackle emergency situations - ...
... research has found that parents can foresee their children's exam ... ,The University of Bath study suggests that English and ... , ,Students with longer ring fingers are more likely ... ring fingers are said to be more proficient at literacy. ...
... demand. Two experts in this weeks BMJ debate whether presumed ... is evidence to the contrary is the answer. ... organ donation, yet only 23% have registered their wish to ... the British Medical Association. ,Research indicates that countries ...
... is widely consumed beverage and is regularly investigated and ... cancer to heart disease. Among its complex effects on ... linked to lower insulin and uric acid levels on ... suggest that coffee consumption may affect the risk of ...
Cached Medicine News:Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 2Health News:Gene Discovery Lays Groundwork for Targeted Therapies for Endometrial Cancer 3Health News:High-fat and Sugary Diet Severely Damage Liver and Other Vital Organs 2Health News:Pediatric Seizure Study Underway in US to Decide Between Diazepam and Lorazepam 2Health News:Pediatric Seizure Study Underway in US to Decide Between Diazepam and Lorazepam 3Health News:Pediatric Seizure Study Underway in US to Decide Between Diazepam and Lorazepam 4Health News:Fingers of Kids can Predict Their Performance in Exams 2Health News:Is Presumed Consent the Answer to Organ Shortages? 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 3
The NexGen CR femoral component is intended for patients who, in the physician's judgement, have good bone stock and whose ligaments provide adequate mediolateral, anteroposterior, and varus/valgus s...
Primary knee system, symmetrical in design....
Cruciate retaining, posterior stabilized and constrained components....
Maximum contact. Minimum wear. Outstanding results....
Medicine Products: